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ABSTRACT 
Mesoporous silica particles (MSP) have been reported to be applicable in diverse situations pertaining to the delivery of several drug molecules. 
MSP have established themselves in treating diseases with oral, dermal and parenteral modes of administration. Recently, dermal delivery using 
MSP have gained a considerable amount of interest owing to the increase in drug stability, permeation and ease of functionalization. MSP, in general, 
have a very high capability of delivering actives ranging from small molecules like drugs and amino acids to larger peptides, vaccines and 
antibodies. The applicability of MSP in achieving desired cosmetic and health-related outcomes depends on the careful tuning of their pore size, 
surface area, shape and overall physicochemical properties. This review provides comprehensive details of the recent developments in the 
fabrication of MSP, their characteristic features and, applications in dermal drug delivery. Studies on establishing the safety profile of MSP have also 
been summarized in the review.  
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The word ‘meso’ alludesto a pore size estimate ranging from 2 to 50 
nm [1]. Majorly reported mesoporous silica particles (MSP) consists 
of oxides of inorganic metals like silica or alumina [2]. Silicon 
dioxide or silica is arranged in various indentations and stacked to 
form different MSP characterized by their pore size, shape and pore 
volume. Broadly silica observed in nature are seen either in their 
amorphous or crystalline structures [3, 4]. MSP are a type of 
synthetic amorphous silica material, consisting of smallest units of 
less than 1 micrometer in diameter. Due to the presence of silanol 
groups on the surface of the MSP, they can form hydrogen bonding 
with various functional groups present on the entrapped molecules 
[5]. A recent trend seen in the utility of MSP are because of their 
surface chemistry mainly consisting of the hydrophilic groups that 
allow for sufficient solubility when given by oral and parenteral 
routes. A simplified surface decorated with silanol groups allows for 
a versatile functionalization in the development of a targeted drug 
delivery system [6]. Low cost of production and ease of large-scale 
transition make it convenient for the industries to prioritize their 
product profile for bulk manufacture of MSP [7]. Till date MSP have 
been reported to be used in drug development [5, 8], diagnosis [9] 
and biomarkers [10], gene delivery [11] and controlled drug release 
systems [12, 13]. The present review is based on the Scopus 
database search with keywords: mesoporous, silica, dermal, drug 
delivery, topical. A comprehensive data has been provided here with 
the search filters ranging from January 2010 to March 2018. 
A wide range of MSP with a uniform pore size which included ordered, 
hallow and rattle types can be synthesized using different surface 
active agents [14]. Due to the wide availableness of various surface 
acting agents,various MSP structures such as Mobil Composition of 
Matter No. 41 and 48 (MCM-41 and MCM-48), Santa Barbara 
amorphous type material (SBA-15 and SBA-16), folded sheets 
mesoporous materials (FSM) and silica particles with bicontinuous 
body-centered (Ia3d) cubic symmetry(KIT-1 and KIT-6) have been 
synthesized [15]. Hollow or rattle type of MSP can obtain high drug 
loading capacity due to their low density of the outer shell of 
mesopores and offer greater specific area. These can be used as drug 
delivery systems rather than conventional systems. Toxicity and 
cellular interaction depend on the chemistry of the surface. Different 
types of functional nanoparticles such as iron oxide, gold etc. can be 
entrapped into the silica providing a way for targeted therapies.  
MSP are chemically synthesized either in the form of ordered or 
unordered particles varying in their internal arrangement involving 
the pores and structures [16, 17]. Several ingredients though 
engaged in the synthesis, main components of MSP system consists 
of a silica precursor and structure directing surfactants. A well-
controlled procedure and description of the characteristics can be 
developed for the synthesis of MSP. Extensive studies being reported 
worldwide on nanoparticles, a relatively newer concept of 
mesoporous silica nanoparticles (MSNP) have emerged. MSP and 
MSNP both are known to increase the solubility of drug molecules, 
provide greater stability to the entrapped molecules [18, 19] and 
enhance their in vivo performance.  
Barriers for the skin delivery 
The skin being the most prominent portion of the human body is the 
most robust barrier to the externally applied molecules [20]. It is 
composed of several layers namely the epidermis, the dermis and 
the hypodermis which is lined by the fatty tissues and the muscle 
layers. A molecule, when applied topically, has to permeate through 
the initial layers of dead cells called the stratum corneum. This 
covering is known to protect the underlying cells very efficiently 
from invading substances and chemicals. Being the most challenging 
barrier to bypass, the stratum corneum is the major hurdle to the 
formulating scientists. Once a molecule has crossed the initial layers 
of the skin, the entry into the systemic circulation and muscular 
tissues is solely dependent on its physicochemical properties. Apart 
from these, the skin is abundantly supplied by the hair follicles and 
sweat glands which also account for the removal of a sufficient 
amount of the dose applied topically [21, 22].  
Dermal applications of MSP  
Though several formulation strategies are available commercially 
like the liposomes, nanostructured lipid carriers and polymeric 
nanoparticle, hydrogels and topical patches there is an unmet need 
for developing an efficient dermal formulation till date [23]. In the 
purview of this, research has been directed towards the utility of 
using the MSP in the dermal and transdermal drug delivery 
applications. MSP due to their unique characteristics [24] and 
compatibility with the skin cells are gaining popularity in the 
cosmetic and dermal drug delivery applications. There are many 
components which affect the transdermal absorption, an active 
process involved in the interaction of a penetrating agent before 
entering into the systemic circulation. However, being in a very 
nascent stage successful MSP based formulation requires several 
factors to be considered and well-controlled parameters like their 
pore size, shape, and duration of exposure, distribution, the effect of 
other excipients and non-toxicity [25]. 
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The drug loading potential, the interaction between host and guest 
molecules and the action of the release profile of the drug can be 
achieved by proper designing and customizing the silica 
nanoparticles [26]. For obtaining a uniform distribution of drugs, 
MSP and MSNP have a free gateway for the drugs to enter despite of 
well-structured channels of silica particles. Biomolecules, on the 
other hand, are having substantial molecular weight and greater 
volumes such as protein molecules and genes need silica particles of 
larger pore size because the diameter of the pore is considered as 
selective size specification for the adsorption of drugs. The 
interaction between the guest and host is primarily a chemical 
bonding between silanol groups and functional groups present on 
the guest molecules (fig. 1). Various surface potentials, and different 
functional groups and lipophilic/lipophobic property of the matrix 
surface can be obtained by modifying the surface of the silica 
particles with the appropriate chemical functionalization. 
Permeation of the MSP through the skin is reported to be highly 
dependent on its physicochemical properties, not limiting to the 
size, agglomeration, shape, porosity, chemical groups present on the 
surface and the integral portions of the pores [27]. It was observed 
that the loading of ketoprofen took place at a higher rate in SBA-15 
than in MCM-41 due to the presence of larger pore size in SBA-15 
[28]. Advances in the analytical techniques have related the effects 
of these properties of MSP with the penetration of the active 
compounds. Much of the attention is focused on the aggregation of 
these MSP and MSPN in the physiological medium and solvents used 
in the routine analysis [29, 30]. Once aggregated they are harder to 
redisperse and hence are unable to be clearly investigated for the 
purpose.  
A handful of studies carried out in this regard show that despite the 
aggregation of MSP the skin cells can uptake the particles to a 
maximum particle size of 75 nm [31]. A slight increase in the particle 
size above this, do not provide for a more significant effect on the 
penetration of the carriers. Another notable approach to increase the 
permeation into the skin is the addition of permeation enhancers and 
functionalization of the carrier molecules. As mentioned earlier, the 
targeting the hair follicles is also an important strategy to increase the 
transdermal delivery of the drugs [32]. A study of the particles with 
nanometer to micrometer sizes was conducted [21] and then 
concluded that optimal penetration was seen in the particles in the 
range of 400–700 nm through the hair follicles. A similar study 
conducted showed that the penetration of the particles begins at 300 
nm and increases until 646 nm after that the hair follicles were unable 
to uptake these particles [33]. Once the particle is in the 
immunogenically accessible layers of the skin, the silica particles in the 
said size range are also reported to cause certain types of toxicity and 
immunogenic reactions [34]. Chemically, the negative charges on the 
surface hinder the penetration into the skin cells hence 
functionalization would be appropriate in ascertaining the entry of 
MSP into the cells. A similar interaction of the MSN surface functional 
groups and the gram-negative and gram-positive bacteria was seen to 
largely inhibit the strains after being loaded with tetracycline [35].  
Biocompatibility of the particles is greatly affected by the surface 
properties of the MSNP. Compared with the neutral and anionic 
analogs, cationic charged analogs are more prone to cytotoxicity and 
produce more immune responses [36]. Upon prolonged exposure of 
silanol groups to the environment, these groups may dismantle the 
structures of lipids, proteins, and other biological molecules. 
PEGylation forms a hydrophilic coating around MSNP which can 
significantly enhance the surface activity, biocompatibility, and 
circulation time (in vivo). A siRNA delivery platform was developed 
by coating the MSNP core with polyethyleneimine and PEG to target 
the heat shock protein (HSP 47) in the treatment of fibrosis. The 
results of the study demonstrated that the MSNP were able to 
reduce the levels of elevated HSP 47 to normal and also provide 
antioxidant properties in in vitro models of the disease [37]. Other 
than PEGylation, the cellular uptake, bio-distribution, excretion, and 
cytotoxicity can be controlled by modifications of MSNP with 
different functional groups such as amino, carboxyl, phenyl 
phosphate, methyl phosphate which includes all kinds groups that 
cause a change in the Zetapotentials [29, 38]. The effect of particle 
shape on the toxicity of nanoparticles, drug performance, and bio 
distribution can be investigated by altering the diameter of the 
particles, different shapes and a relation between the bio-
compatibility and the particle shape can be obtained.  
 
 




The topmost layer of the skin sharing the air interface is the stratum 
corneum. Like most other barriers, it also has an affinity for 
lipophilic moieties and favorably transports the substances tagged 
with a lipid-like compound. The explanation further moves on into 
the barrier preventing the entry of lipophobic or hydrophilic 
molecules through it. It is well-advised that a compound to be able 
to breach the stratum corneum has to possess considerable 
lipophilicity as well as slight hydrophilicity to be able to be 
formulated into an effective system. MSP offer a considerable 
amount of both these properties to the entrapped molecules thereby 
facilitating the entry of the entrapped molecules into the skin cells 
[39]. Agglomeration, on the other hand, prevents the smooth 
passage of the carrier systems into the cells due to the increase in 
the size of the particles and reduction in the surface area, which in 
turn elicits an immunogenic reaction on sufficient exposure. Skin in 
itself is a barrier that has a slightly acidic pH of about 6.8 thus 
allowing it to be highly efficient in its purpose of the activity. 
Therefore the ionization of the MSP and the drug moieties play a 
crucial role in such cases where the absorption is said to be pH 
dependent [40]. Contrary to the fact that the particles of size 300 to 
600 nm was found to be well concentrated in the cellular systems, 
the particles of size above 3 micrometers were also seen to 
penetrate well into the dermis [41]whereas the concentration into 
the epidermis was possible only with an ethanolic medium (65 %). 
Adding onto the theories that oil and lipid-like molecules were able 
to bypass the stratum corneum, the coating of MSP and MSNP have 
been looked as an excellent strategy for the dermal or transdermal 
therapy. Several lipids such as lecithin and other phospholipids, and 
emulsion coating [42] have been coated onto the MSP, and the 
results have shown the extensive stability of the particles and 
sufficient penetration into the deeper skin layers. Substances like 
the retinol [43], quercetin and rutin [44, 45] have been explicitly 
studied in conjunction with the MSP coated with the oil-based 
emulsions. All-trans-retinol, when formulated as oil-in-water 
emulsions coated onto MSNP, showed that the stability was 
improved two times compared to the oleylamine-and lecithin-
stabilized droplets [43]. Flavonoids such as quercetin and rutin were 
loaded on to MSP functionalized with titanium. The results showed 
that the free radical scavenging of the ethanolic citric acid recovered 
and the bound flavonoids were greater than 80% [44]. Penetration 
in certain cases is not desirable due to the objective of treating the 
superficial or conditions encircling the dermis or the epidermis. In 
these type of applications, penetration retarders are known to serve 
the purpose. Recently emulsions and MSP together constituting the 
barrier-like function have been explored for the delivery of caffeine. 
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It was shown that there was a delayed penetration of the active 
through the pigskin in comparison with the reference gel.  
Other factors 
Despite taking enormous precautions and carefully selecting the ranges 
of the components to obtain the desired functional characteristics of 
MSP and MSNP for the topical administration, specific factors still exist 
which are out of the control of the formulators. Majorly the exfoliation, 
sweating and transfer to external surfaces from the skin represent the 
concerns for the failure of the well-formulated product [45]. Certain 
molecules that are to be entrapped into the MSP are sensitive to light, 
oxygen, and moisture. Even though the MSP are highly regarded as a 
system to provide stability, these conditions may pose unavoidable 
problems in a formulation [46, 47].  
Preparation methods of MSPs and MSNPs 
There are three ways by which functionalities are integrated with 
silica particles:  
a) Grafting method (in which silica nanoparticles are succeeding 
attached by organic compounds) 
b) Upon co-condensation of silica particles and the organic 
compounds containing silyl group (R3Si) 
c) Formation of periodic mesoporous organosilicas (PMO) with the 
help of organic precursors which are bissilyated.  
Grafting method 
The major principle involved in the grafting is the reaction of 
organosilanes with the unreacted silanol groups present on the silica 
surface. Some of the silanes include organo, chloro or silazanes. The 
word grafting mainly alludes to sequential modification of internal 
pore surfaces of mesoporous silica phases with organic compounds 
[48, 49]. The uniformity of the distribution of organic compounds 
over the silica surface depends on the size of the organic compound 
and the degree of tenancy, in turn, leads to the abnormal diffusion of 
more amount of molecules into the pores present on the silica 
surface which leads to the blockade of pores, thus creating an 
ordered or unordered pore system.  
Co-condesation of silica particles 
Functionalized MSP can be achieved by co-condensation of type (R ′O)3-
alkoxysilanes and (RO)4
Formation of PMOs 
-alkoxysilanes where MCM-41 and SBA-15 acts 
as a structure-directing agent present on the pore walls so that organic 
residues are obtained. The primary advantage of this method is that less 
blockade of pores are seen due to the presence of organic functionalities 
which discharge into the pores of the silica particles and organic 
particles are uniformly distributed over the pores of silica particles when 
compared with the grafting process [50, 51]. The drawbacks of this 
method include improper functionalization can occur, and the 
proportion of concentration of organic groups present on the pore walls 
varies leading to lower concentrations at the extreme groups compared 
with the initial groups. Another drawback is that upon an increase in 
incorporation of organic functionalities, a decrease in the size of the 
pore, volume of the pore and the surface area is seen.  
PMO contain a tapered pore radius because the integrated 
compounds of silica are formed by the organic bridges between 
surface active agents acting on bisilyatedorganosilica precursors and 
mesoporos silica particles [52, 53]. PMO are extensively used in the 
preparation of active payloads. 
Safety concerns  
All kinds of materials applied over the skin with theintention of 
concentrating in the upper and deeper layers of the skin, the entry 
into the systemic circulation and their effect on distal organs have to 
be clearly addressed. Most commonly reported issues of toxicity 
with such formulations include the primary inflammatory responses 
upon contact of the actives and carriers with the epidermis which 
may then progress to the dermis producing allergic reactions [54]. 
Effects of the systemic exposure can also be seen in the distal organs 
upon prolonged exposure to the formulation and can also lead to 
certain types of cancer [55]. MSP are also not free from these kinds 
of complications that may be fatal in the long run [56]. Therefore it 
is very important to address these concerns especially in the case of 
MSNP clearly. The safety concerns can be adequately addressed with 
modern analytical techniques like the transmission electron 
microscopy (TEM), Raman scattering and using fluorescent probes 
in a confocal laser microscopy system. Apart from in vivo safety 
concerns, MSP are released into the environment by a variety of 
common industrial processes [57].  
CONCLUSION 
MSP and MSNP are more adaptable, flexible, and stronger than 
traditional drug delivery frameworks, for example, polymer 
nanoparticles and liposomes. The confinements of regular natural 
systems are low medication stacking limit, low produce, and high-
price of generation. With the extraordinary mesoporous structure and 
high surface region, MSP as carriers have a high ability to oblige guest 
particles and can discharge the stacked particles in physiologic 
conditions. Their pore structure with capable pore size and geometry 
encourages a similar joining of guest particles with various sizes and 
surface groups. The fabrication procedure is moderately basic, and the 
price is fundamentally low, which is critical to satisfy the intended 
clinical request concerning the dermal delivery of actives.  
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